Enanta sells off over 50% of royalty payments from Mavyret in exchange for $200M
Enanta Pharmaceuticals is selling off royalty payments from its AbbVie-partnered drug Mavyret, its biggest revenue driver, to a Canadian pension plan for $200 million.
Enanta has sold 54.5% of its future worldwide Mavyret royalty payments from AbbVie to OMERS, a Canadian defined benefit pension plan, in exchange for $200 million beginning in July 2023 until June 2032. The royalty payments are based on net sales of Mavyret during that time period, with total payments capped at 1.42 times the purchase price, or $284 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.